Last reviewed · How we verify

NCT03524781

Treatment of Newly Diagnosed Gastroesophageal Reflux Disease in a National Population-based Cohort

Completed Last updated 4 August 2020
What this trial tests

trial in Gastroesophageal Reflux in 36,292 participants. Completed in 1 August 2020.

Timeline
2 May 2018
Primary endpoint
1 January 2019
1 August 2020

Quick facts

Lead sponsorUniversity of Southern Denmark
StatusCompleted
Study typeOBSERVATIONAL
Enrollment36,292
Start date2 May 2018
Primary completion1 January 2019
Estimated completion1 August 2020
Sites1 location across Denmark

Conditions studied

Sponsor

University of Southern Denmark

Who can join

18 and older, any sex, with Gastroesophageal Reflux. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the treatment of newly diagnosed gastro-esophageal reflux disease in a Danish national cohort, comparing medical and surgical treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Gastroesophageal Reflux

Currently open trials in the same condition.

Other University of Southern Denmark trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03524781.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing